It is sad.
But what else can you do, other than provide information ? - of course they're going to ignore it, and yell "
Orange man BAD !!" No matter what.
More information...
-------------------------------------------------
COVID-19 Drug Therapy
Tim Smith, PharmD, BCPS; Jennifer Bushek, PharmD; Tony Prosser, PharmD
Clinical Drug Information | Clinical Solutions
. Several agents are being used under clinical trial and compassionate use protocols based on in vitro activity (against SARS-CoV-2 or related viruses) and on limited clinical experience. Efficacy has not been established for any drug
therapy.
o Chloroquine – In vitro and limited clinical data suggest potential benefit.
o Hydroxychloroquine – In vitro and limited clinical data suggest potential benefit.
o Lopinavir; Ritonavir - Role in the treatment of COVID-19 is unclear. Preclinical datasuggested potential benefit; however, more recent data has failed to confirm.
o Remdesivir – Investigational and available only through expanded access and study protocols; several large clinical trials are underway.
o Azithromycin – Used in some protocols based on theoretical mechanism and limited preliminary data as adjunct therapy.
o Tocilizumab – Immunomodulating agent used in some protocols based on theoretical mechanism and limited preliminary data as adjunct therapy.
o COVID-19 convalescent plasma – Investigational use is being studied
Chloroquine: Chloroquine has in vitro activity against SARS-CoV-2 and may have immunomodulating properties.
Mechanisms may include inhibition of viral enzymes or processes such as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus particle transport, and virus release. Other mechanisms may also involve ACE2
cellular receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the virus, and immunomodulation of cytokine release.
Pre-clinical data in vitro suggest chloroquine has activity has activity against SARS-CoV-2
There have been reports of potential benefit in inhibiting the exacerbation of pneumonia patients with SARS-CoV-2 infection; however, specific data are not available.
https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf
----------------------------------------------------
Give them information, if they choose to keep entertaining their mindless hate, it will only hurt them. Hate is a destructive force for those who engage it long-term.